Cas No. 855778-84-6, 3-(piperidin-4-yl)quinolin-2(1h)-one hydrochloride

Zavegepant offers a transformative approach to migraine treatment by targeting the underlying cause of migraine attacks. With its efficacy in reducing migraine severity and frequency, Zavegepant holds immense value in the field of neurology. Seamlessly incorporate our intermediates into your manufacturing process, ensuring a consistent supply of this exceptional medication. Join us in revolutionizing the management of migraines and improving the lives of millions of sufferers. Embrace Zavegepant and redefine the future of migraine therapy.

A Witty reagent such as Trimethyl phosphonoacetate (CAS No. 5927-18-4) is used to synthesize this compound CAS No. 855778-84-6, followed by catalyzed hydrogenation.

CAS No. 855778-84-6 then reacts with CAS No. 1414976-14-9 to yield the N-1 Zavegepant intermediate.